November 17th, 2026Takeda launches Orzeyful, first orexin agonist for narcolepsy type 1Takeda’s Orzeyful, the first orexin agonist for narcolepsy type 1, is now available in the U.S. at a whole acquisition list price of $16,500 per 60-tablet bottle.Read more
November 17th, 2026From Keytruda biosimilar to novel ADC: Samsung Bioepis’ 2-track oncology strategySBE303, a Nectin-4 ADC for previously treated bladder cancer, is in phase 1 as the company advances SB27, its proposed Keytruda biosimilar.Read more